These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 28042780)

  • 1. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus.
    Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N
    Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.
    Kurokawa C; Iankov ID; Anderson SK; Aderca I; Leontovich AA; Maurer MJ; Oberg AL; Schroeder MA; Giannini C; Greiner SM; Becker MA; Thompson EA; Haluska P; Jentoft ME; Parney IF; Weroha SJ; Jen J; Sarkaria JN; Galanis E
    J Natl Cancer Inst; 2018 Oct; 110(10):1123-1132. PubMed ID: 29788332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Oncolytic Properties of a Mumps Virus Vaccine Strain in Human Melanoma Cell Lines].
    Ammour YI; Ryabaya OO; Milovanova AV; Sidorov AV; Shohin IE; Zverev VV; Nasedkina TV
    Mol Biol (Mosk); 2018; 52(4):659-666. PubMed ID: 30113031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus.
    Ammour Y; Ryabaya O; Shchetinina Y; Prokofeva E; Gavrilova M; Khochenkov D; Vorobyev D; Faizuloev E; Shohin I; Zverev VV; Svitich O; Nasedkina T
    Viruses; 2020 Feb; 12(2):. PubMed ID: 32033013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
    Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
    Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.
    Delaunay T; Achard C; Boisgerault N; Grard M; Petithomme T; Chatelain C; Dutoit S; Blanquart C; Royer PJ; Minvielle S; Quetel L; Meiller C; Jean D; Fradin D; Bennouna J; Magnan A; Cellerin L; Tangy F; Grégoire M; Fonteneau JF
    J Thorac Oncol; 2020 May; 15(5):827-842. PubMed ID: 31945495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
    Haralambieva I; Iankov I; Hasegawa K; Harvey M; Russell SJ; Peng KW
    Mol Ther; 2007 Mar; 15(3):588-97. PubMed ID: 17245355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
    Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
    Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
    Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
    Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant measles virus vaccine strain rMV-Hu191 has oncolytic effect against human gastric cancer by inducing apoptotic cell death requiring integrity of lipid raft microdomains.
    Lv Y; Zhou D; Hao XQ; Zhu MY; Zhang CD; Zhou DM; Wang JH; Liu RX; Wang YL; Gu WZ; Shen HQ; Chen X; Zhao ZY
    Cancer Lett; 2019 Sep; 460():108-118. PubMed ID: 31226409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.
    Lal S; Carrera D; Phillips JJ; Weiss WA; Raffel C
    Neuro Oncol; 2018 Nov; 20(12):1606-1615. PubMed ID: 29912438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
    Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
    Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment.
    Chatelain C; Berland L; Grard M; Jouand N; Fresquet J; Nader J; Hirigoyen U; Petithomme T; Combredet C; Pons-Tostivint E; Fradin D; Treps L; Blanquart C; Boisgerault N; Tangy F; Fonteneau JF
    Oncoimmunology; 2024; 13(1):2377830. PubMed ID: 39005546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.
    Lühl NC; Zirngibl F; Dorneburg C; Wei J; Dahlhaus M; Barth TF; Meyer LH; Queudeville M; Eckhoff S; Debatin KM; Beltinger C
    Haematologica; 2014 Jun; 99(6):1050-61. PubMed ID: 24700491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
    Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice.
    Lal S; Peng KW; Steele MB; Jenks N; Ma H; Kohanbash G; Phillips JJ; Raffel C
    Hum Gene Ther Clin Dev; 2016 Dec; 27(4):145-151. PubMed ID: 27604429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.
    Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW
    BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo.
    Künzi V; Oberholzer PA; Heinzerling L; Dummer R; Naim HY
    J Invest Dermatol; 2006 Nov; 126(11):2525-32. PubMed ID: 16960554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
    Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
    Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.